Published in Nature on April 09, 2009
Molecular Profiling of Colorectal Cancer | NCT04863768
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications | NCT05119829
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res (2009) 28.60
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science (2015) 21.42
International network of cancer genome projects. Nature (2010) 20.35
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
The DNA-damage response in human biology and disease. Nature (2009) 17.86
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Regulation of cancer cell metabolism. Nat Rev Cancer (2011) 15.44
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell (2011) 10.50
Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet (2010) 10.15
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22
Interactome networks and human disease. Cell (2011) 7.16
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science (2012) 6.79
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays (2011) 5.01
TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol (2010) 4.92
An integrated approach to uncover drivers of cancer. Cell (2010) 4.53
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep (2013) 3.92
Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell (2011) 3.81
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Automated network analysis identifies core pathways in glioblastoma. PLoS One (2010) 3.64
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A (2013) 3.15
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature (2016) 3.05
Interpreting noncoding genetic variation in complex traits and human disease. Nat Biotechnol (2012) 3.01
Making sense of cancer genomic data. Genes Dev (2011) 3.01
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Analysis of the human endogenous coregulator complexome. Cell (2011) 2.97
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91
High order chromatin architecture shapes the landscape of chromosomal alterations in cancer. Nat Biotechnol (2011) 2.63
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol (2012) 2.56
Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50
Origins of metastatic traits. Cancer Cell (2013) 2.49
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol (2012) 2.39
cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res (2012) 2.36
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell (2013) 2.34
Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell (2013) 2.32
High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell (2016) 2.31
Single cell genomics: advances and future perspectives. PLoS Genet (2014) 2.16
Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol (2011) 2.15
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Probing the probes: fitness factors for small molecule tools. Chem Biol (2010) 2.08
A Landscape of Pharmacogenomic Interactions in Cancer. Cell (2016) 2.07
Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06
Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med (2010) 2.04
The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkers. Neurosurgery (2014) 2.02
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers. Rejuvenation Res (2014) 2.02
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99
Cancer vulnerabilities unveiled by genomic loss. Cell (2012) 1.95
Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res (2012) 1.95
Lung cancer cell lines as tools for biomedical discovery and research. J Natl Cancer Inst (2010) 1.92
A cancer theory kerfuffle can lead to new lines of research. J Natl Cancer Inst (2014) 1.91
Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol (2013) 1.91
Clock-like mutational processes in human somatic cells. Nat Genet (2015) 1.91
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa. BMC Biol (2010) 1.87
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations. PLoS One (2010) 1.85
Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples. BMC Med Genomics (2011) 1.84
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood (2014) 1.81
The cancer antigenome. EMBO J (2012) 1.78
Single-cell paired-end genome sequencing reveals structural variation per cell cycle. Nucleic Acids Res (2013) 1.77
In vivo identification of regulators of cell invasion across basement membranes. Sci Signal (2010) 1.77
The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers. Adv Immunol (2010) 1.77
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
High-throughput sequencing for biology and medicine. Mol Syst Biol (2013) 1.75
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One (2012) 1.72
Mechanisms and insights into drug resistance in cancer. Front Pharmacol (2013) 1.70
Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing. J Vis Exp (2013) 1.68
Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet (2014) 1.68
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature (1953) 47.27
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III. J Exp Med (1944) 24.08
Genetic instabilities in human cancers. Nature (1998) 22.76
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 15.28
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50
Mechanism of activation of a human oncogene. Nature (1982) 12.09
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
Targeted cancer therapy. Nature (2004) 7.81
End-sequence profiling: sequence-based analysis of aberrant genomes. Proc Natl Acad Sci U S A (2003) 7.70
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci U S A (2008) 7.22
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature (1981) 4.72
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Transforming activity of human tumor DNAs. Proc Natl Acad Sci U S A (1981) 4.02
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
Telomeres: cancer to human aging. Annu Rev Cell Dev Biol (2006) 2.88
DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol (2006) 2.49
Cancers exhibit a mutator phenotype: clinical implications. Cancer Res (2008) 2.36
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Genetic instability is not a requirement for tumor development. Cancer Res (2008) 1.68
Oncogenic transformation and experimental models of human cancer. Front Biosci (2008) 1.59
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol (2008) 1.58
Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol (2008) 1.55
On the nature of susceptibility to cancer. The presidential address. Cancer (1980) 1.49
Retroviral insertion mutagenesis in mice as a comparative oncogenomics tool to identify disease genes in human leukemia. Mol Ther (2007) 1.39
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program (2008) 1.32
Viruses and tumours--an update. Eur J Cancer (2004) 1.23
Aneuploidy-cancer predisposition syndromes: a new link between the mitotic spindle checkpoint and cancer. Cell Cycle (2005) 1.21
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18
The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. Genome Res (2007) 6.91
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics (2004) 5.65
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics (2006) 5.56
High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res (2004) 5.24
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res (2007) 4.99
Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet (2012) 4.82
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res (2012) 4.34
RNA editing of human microRNAs. Genome Biol (2006) 4.16
A survey of RNA editing in human brain. Genome Res (2004) 4.14
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ (2008) 4.04
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Chromosomal instability confers intrinsic multidrug resistance. Cancer Res (2011) 3.70
Cancer genomics: from discovery science to personalized medicine. Nat Med (2011) 3.66
Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet (2012) 3.63
Deciphering signatures of mutational processes operative in human cancer. Cell Rep (2013) 3.61
Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther (2006) 3.56
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2012) 3.43
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Evolution of the cancer genome. Nat Rev Genet (2012) 3.24
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 2.98
Data mining using the Catalogue of Somatic Mutations in Cancer BioMart. Database (Oxford) (2011) 2.84
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood (2010) 2.83
DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife (2013) 2.67
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet (2011) 2.52
Criteria for inference of chromothripsis in cancer genomes. Cell (2013) 2.51
Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adolescents and adults. Genes Chromosomes Cancer (2006) 2.50
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell (2012) 2.37
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. Nat Genet (2007) 2.35
SLC9A6 mutations cause X-linked mental retardation, microcephaly, epilepsy, and ataxia, a phenotype mimicking Angelman syndrome. Am J Hum Genet (2008) 2.16
Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer (2010) 2.11
Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. Nat Genet (2006) 2.08
Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci Transl Med (2013) 2.07
Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor. Am J Hum Genet (2007) 2.07
Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation. Am J Hum Genet (2004) 2.04